Physician profile
Erwin Ramos
NPI 1235396326
$10,998.04
in general payments reported to CMS, 2019-2025
22 companies · $8,833 in 2025
The $8,833 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $322 · 2021: $324 · 2022: $392 · 2023: $173 · 2024: $192 · 2025: $8,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $8,405 · Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $8,405.00 |
| Food and Beverage | $793.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $8,543.92 | 2019-2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $519.20 | 2019-2025 | Rexulti |
| Corium, LLC | $346.91 | 2022-2025 | Azstarys |
| Lundbeck LLC | $329.53 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $269.42 | 2019-2025 | Trintellix |
| Adlon Therapeutics L.P. | $152.26 | 2019-2021 | |
| Bausch Health US, LLC | $142.48 | 2019-2021 | |
| Tris Pharma INC | $141.94 | 2022-2024 | Dyanavel Xr |
| Abbvie INC. | $101.82 | 2021-2023 | |
| Almatica Pharma LLC | $96.23 | 2024-2025 | Loreev Xr |
| Eisai INC. | $68.46 | 2020-2021 | |
| Livanova USA, INC. | $57.15 | 2022 | |
| Allergan, INC. | $41.45 | 2019 | |
| Axsome Therapeutics, INC. | $41.23 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.72 | 2024-2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $22.29 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $16.59 | 2024 | |
| Supernus Pharmaceuticals, INC. | $15.26 | 2021 | |
| Alkermes, INC. | $14.61 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $12.99 | 2022 | |
| Shire North American Group INC | $11.84 | 2019 | |
| Boston Scientific Corporation | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.